Translational Studies in FLASH Particle Radiotherapy

FLASH粒子放射治疗的转化研究

基本信息

  • 批准号:
    10333797
  • 负责人:
  • 金额:
    $ 247.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-02-15 至 2027-01-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Radiation therapy (RT) is used in the curative setting for many cancers including sarcomas and lung and pancreatic cancer. Despite significant improvements over the past few decades, there is still much room for improvement as patients still develop RT-induced injuries or second malignant neoplasms. FLASH radiotherapy, which delivers a large dose of radiation at an ultra-high dose rate could potentially reduce toxicity. Our overall hypothesis is that Proton/Carbon Particle FLASH RT is superior to Standard Particle RT in protecting normal tissues while the two modalities will be equipotent in controlling malignant growth. Project 1, which focuses on pancreatic cancer, will define the dosimetric and biophysical parameters that will maximally spare normal intestine tissues using FLASH proton therapy (F-PRT) without compromising antitumor effects. It will delineate mechanistic aspects of differential response of normal intestinal tissues, by focusing on the relative sparing of the stem/progenitor cell population. Project 1 will also employ p53+/- transgenic mouse models to dissect the genetic determinants of differential GI toxicity of Standard proton therapy (S-PRT) vs F-PRT. Project 2 will explore the ability of F-PRT to ameliorate adverse events (inflammation, fibrosis, lymphedema, changes to bone structure, radiation-induced cancers) that pose barriers to the treatment of sarcomas with RT. We will also carry out a phase 1/2 trial that will treat canine patients with osteosarcomas definitively with F-PRT. Project 3 will compare the efficacy of FLASH-RT given with carbon ion radiotherapy (C- RT) vs. standard dose rate and compare it to electron F-RT. Studies will focus on the mitigation of normal tissue injury in NSCLC with an emphasis on the impact of normal tissue and intratumoral hypoxia to response following C-RT. Lastly, Project 4 will develop and validate the use of pencil beam scanning (PBS) technology for particle F-RT. It will analyze spatiotemporal variations and SOBP (spread out Bragg peak) vs. shoot through PBS and develop dose delivery algorithms for modeling biological effects for PBS-based FLASH proton therapy. These tools will be incorporated in the experimental plans of project 1-3. These Projects are supported by 4 Cores including an Administrative Core (Core A), Physics-Dosimetry Core (Core B), which will offer infrastructure services to harmonize dosimetry between various sites and a Comparative Pathology core (Core C) for tissue preparation for histopathological evaluation. Statistical services will be provided by Core D. Collectively, this highly integrated effort led by recognized leaders in Radiation and Tumor Biology, aims to define the biological, dosimetric and biophysical parameters and molecular mechanisms under which FLASH RT is most effective in tumors and tissues we deem the most likely to be first tested in clinical trials. It is our belief that only by acquiring this knowledge will this exciting and novel modality be ushered into the clinic in a safe and effective manner to improve therapeutic outcome and quality of life of cancer patients.
项目摘要 放射疗法(RT)用于治疗许多癌症,包括肉瘤和肺癌, 胰腺癌尽管在过去几十年中取得了重大进展,但仍有很大的空间, 改善,因为患者仍然发展RT诱导的损伤或第二恶性肿瘤。FLASH放疗, 其以超高剂量率递送大剂量辐射,可以潜在地降低毒性。我们的整体 假设质子/碳粒子FLASH RT在保护方面上级标准粒子RT, 正常组织,而这两种模式在控制恶性生长方面是等效的。 项目1侧重于胰腺癌,将确定剂量和生物物理参数, 使用FLASH质子治疗(F-PRT)将最大限度地保留正常肠组织, 抗肿瘤作用它将描绘正常肠组织的不同反应的机制方面, 集中于干/祖细胞群体的相对保留。项目1也将采用p53+/-转基因 用于剖析标准质子治疗(S-PRT)的不同GI毒性的遗传决定因素的小鼠模型 相对于F-PRT。项目2将探索F-PRT改善不良事件(炎症,纤维化, 水肿、骨结构变化、辐射诱发的癌症),这些疾病对治疗 我们还将进行一项1/2期试验,将治疗患有骨肉瘤的犬患者 最终与F-PRT。项目3将比较FLASH-RT与碳离子放射治疗(C- RT)与标准剂量率,并将其与电子F-RT进行比较。研究将侧重于正常组织的缓解 NSCLC中的损伤,重点是正常组织和肿瘤内缺氧对以下反应的影响 最后,项目4将开发和验证笔形束扫描(PBS)技术在粒子成像中的应用。 它将分析时空变化和SOBP(扩展布拉格峰)与通过PBS拍摄, 开发剂量输送算法,用于对基于PBS的FLASH质子治疗的生物效应进行建模。这些 这些工具将纳入项目1-3的实验计划。这些项目由4个核心支持 包括管理核心(核心A)、物理剂量核心(核心B),它们将提供基础设施 协调不同部位之间的剂量测定和组织比较病理学核心(核心C)的服务 组织病理学评价准备。统计服务将由核心D提供。 总的来说,由辐射和肿瘤生物学领域公认的领导者领导的这一高度综合的努力旨在 定义生物学、剂量学和生物物理学参数以及FLASH RT在我们认为最有可能首先在临床试验中进行测试的肿瘤和组织中最有效。是我们 相信只有通过获得这些知识,这种令人兴奋的和新颖的形式才能被引入 以安全有效的方式改善癌症患者的治疗效果和生活质量。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Constantinos Koumenis其他文献

Constantinos Koumenis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Constantinos Koumenis', 18)}}的其他基金

Translational Studies in FLASH Particle Radiotherapy
FLASH粒子放射治疗的转化研究
  • 批准号:
    10573278
  • 财政年份:
    2022
  • 资助金额:
    $ 247.85万
  • 项目类别:
Core A: Administrative Core
核心A:行政核心
  • 批准号:
    10333802
  • 财政年份:
    2022
  • 资助金额:
    $ 247.85万
  • 项目类别:
Project 1: FLASH vs. Standard radiotherapy for treatment of PDAC and sparing normal intestine tissues
项目 1:FLASH 与标准放疗治疗 PDAC 并保护正常肠道组织
  • 批准号:
    10573280
  • 财政年份:
    2022
  • 资助金额:
    $ 247.85万
  • 项目类别:
Project 1: FLASH vs. Standard radiotherapy for treatment of PDAC and sparing normal intestine tissues
项目 1:FLASH 与标准放疗治疗 PDAC 并保护正常肠道组织
  • 批准号:
    10333798
  • 财政年份:
    2022
  • 资助金额:
    $ 247.85万
  • 项目类别:
Core A: Administrative Core
核心A:行政核心
  • 批准号:
    10573304
  • 财政年份:
    2022
  • 资助金额:
    $ 247.85万
  • 项目类别:
Targeting the Integrated Stress Response effector ATF4 for mitigation of treatment-induced fibrosis
靶向综合应激反应效应器 ATF4 以减轻治疗引起的纤维化
  • 批准号:
    10324364
  • 财政年份:
    2021
  • 资助金额:
    $ 247.85万
  • 项目类别:
Core B: Small Animal Radiation Core
核心B:小动物辐射核心
  • 批准号:
    10360421
  • 财政年份:
    2017
  • 资助金额:
    $ 247.85万
  • 项目类别:
Core B: Small Animal Radiation Core
核心B:小动物辐射核心
  • 批准号:
    10005187
  • 财政年份:
    2017
  • 资助金额:
    $ 247.85万
  • 项目类别:
Improving radiation response by targeting O2 metabolism via the PI3K/mTOR pathway
通过 PI3K/mTOR 通路靶向 O2 代谢来改善放射反应
  • 批准号:
    8886591
  • 财政年份:
    2015
  • 资助金额:
    $ 247.85万
  • 项目类别:
Program as an Integrated Effort
计划作为一项综合工作
  • 批准号:
    8596402
  • 财政年份:
    2013
  • 资助金额:
    $ 247.85万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 247.85万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 247.85万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 247.85万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 247.85万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 247.85万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 247.85万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 247.85万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 247.85万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 247.85万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 247.85万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了